SCHEMBL9541397

SCHEMBL9541397

CC(C)(C)[Si](C)(C)Oc1cccc2cccnc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
KDM4E B2RXH2 9/20 0.49
RAB9A P51151 5/20 0.48
NPC1 O15118 4/20 0.48
USP2 O75604 1/20 0.47
MAPT P10636 6/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
GAA P10253 1/20 0.47
POLB P06746 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
MAPK1 P28482 1/20 0.46
CYP2C19 P33261 1/20 0.46
METAP2 P50579 2/20 0.44
METAP1 P53582 2/20 0.44
HDAC6 Q9UBN7 1/20 0.44
GMNN O75496 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxyquinoline SCHEMBL26921554 0.91 METAP2 (0.58) LMNASMN1; SMN2KDM4ERAB9ANPC1
SCHEMBL250695 0.82 KDM4E (0.54) LMNASMN1; SMN2KDM4ERAB9ANPC1
SCHEMBL25212734 0.80 KDM4E (0.41) LMNAKDM4ERAB9AUSP2MAPT
SCHEMBL3464510 0.79 MEN1 (0.50) LMNASMN1; SMN2KDM4ERAB9AMEN1
SCHEMBL4151477 0.78 RAB9A (0.49) LMNASMN1; SMN2KDM4ERAB9ANPC1
SCHEMBL21225851 0.78 MCHR1 (0.45)
SCHEMBL1101316 0.77 KDM4E (0.53) LMNASMN1; SMN2KDM4ERAB9ANPC1
SCHEMBL6269386 0.77 NFE2L2 (0.33) LMNASMN1; SMN2MAPTGAAMAPK1
SCHEMBL15180209 0.76 KMT2A (0.47) LMNASMN1; SMN2KDM4ENPC1USP2
SCHEMBL18318478 0.76 LMNA (0.44) LMNASMN1; SMN2KDM4ERAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109900-A1 AZABICYCLIC SHP2 INHIBITORS PROMIDIS S.R.L. (IT) 2024-04-04 US disclosed
EP-4288431-A1 AZABICYCLIC SHP2 INHIBITORS IRBM S.P.A. (IT) 2023-12-13 EP disclosed
WO-2022167682-A1 AZABICYCLIC SHP2 INHIBITORS IRBM S.P.A. (IT) 2022-08-11 WO disclosed
US-9741944-B2 Materials for organic electroluminescent devices MERCK PATENT GMBH (DE) 2017-08-22 US disclosed
US-20170012221-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2017-01-12 US disclosed
US-9409883-B2 Materials for organic electroluminescent devices MERCK PATENT GMBH (DE) 2016-08-09 US disclosed
US-20120292571-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2012-11-22 US disclosed
WO-1993003719-A1 ARYLALKYLETHER AND ARYLALKYLTHIOETHER INHIBITORS OF LIPOXYGENASE ENZYME ACTIVITY ABBOTT LABORATORIES (US) 1993-03-04 WO disclosed
US-5183818-A Also for inhibiting leukotriene biosynthesis ABBOTT LABORATORIES (US) 1993-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109900-A1 AZABICYCLIC SHP2 INHIBITORS PTPN22, PTPN2, PTPN5 LMNA 4847/4885SMN1; SMN2 4426/4885KDM4E 411/4885
US-20120292571-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES EPCAM, SLC39A3, L1CAM LMNA 2617/4885SMN1; SMN2 4287/4885KDM4E 2789/4885
US-20170012221-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES EPCAM, SLC39A3, L1CAM LMNA 2617/4885SMN1; SMN2 4287/4885KDM4E 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.